Biodesix(US:BDSX) Globenewswire·2025-11-03 21:01Core Insights - Biodesix, Inc. reported a strong third quarter for 2025 with revenue of $21.8 million, reflecting a 20% increase compared to Q3 2024 [1][2] - The company improved its gross profit margin to 81%, marking a 400-basis point enhancement year-over-year [1][2] - Biodesix raised its total revenue guidance for FY2025 to a range of $84 million to $86 million [1][6] Financial Results - Total revenue for Q3 2025 was $21.8 million, a 20% increase from the prior year [5] - Lung Diagnostic Testing revenue reached $19.8 million, up 16% year-over-year, driven by increased tests delivered and higher average revenue per test [5] - Development Services revenue surged to $1.9 million, a 97% increase year-over-year, attributed to fulfilling contracted business and securing new agreements [5] - Gross margin was $17.7 million, or 81%, reflecting a 400-basis point improvement due to growth in Lung Diagnostic testing and cost optimizations [5] - Operating expenses for Q3 2025 were $24.7 million, a 10% increase from the previous year, primarily due to higher sales and marketing costs [5] - The net loss for Q3 2025 was $8.7 million, an improvement of 15% compared to the same period last year [5] - Adjusted EBITDA loss was $4.6 million, an 18% improvement year-over-year [5] Business Highlights - Lung Diagnostic Tests ordered in primary care increased by over 75% compared to Q3 2024 [12] - The Development Services business reported $12.9 million under contract, a 16% increase year-over-year [12] - Biodesix expanded its partnership with Bio-Rad Laboratories to develop high complexity assays [12] - A Research and Development Corporate Workshop is scheduled for November 12, focusing on the company's R&D efforts and partnerships [12]